Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03550391 · ClinicalTrials.gov registry record · Phase 3

Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases

A Phase 3 study of Brain Metastases, sponsored by Canadian Cancer Trials Group.

Compiled by PlainTrial · August 8, 2026

Recruiting
Registry status: Phase 3
Development phase: 206
Enrollment target: 20
Study locations

NCT03550391: Recruiting Phase 3 study of Brain Metastases, sponsored by Canadian Cancer Trials Group.

NCT03550391 is a Phase 3 study of Brain Metastases that is actively recruiting participants, run by Canadian Cancer Trials Group. The registered enrollment target is 206 participants, roughly in line with the 210-participant average among 67 other Brain Metastases trials with a reported enrollment target. The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03550391, a Phase 3 study of Brain Metastases, is actively recruiting participants, sponsored by Canadian Cancer Trials Group.

RECRUITING
Registry status: Phase 3
Development phase: 206 participants
Enrollment target: 20
Study locations

Study Summary

Stereotactic radiosurgery (SRS) is a commonly used treatment for brain tumors. It is a one-day (or in some cases two day), out-patient procedure during which a high dose of radiation is delivered to small spots in the brain while excluding the surrounding normal brain. Whole brain radiation therapy with hippocampal avoidance (HA-WBRT) is when radiation therapy is given to the whole brain, while trying to decrease the amount of radiation that is delivered to the area of the hippocampus. The hippocampus is a brain structure that is important for memory. Memantine is a drug that is given to help relieve symptoms that can be caused by WBRT, including problems with memory and other mental symptoms. Health Canada, the regulatory body that oversees the use of drugs in Canada, has not approved the sale or use of memantine in combination with WBRT to treat this kind of cancer, although they have allowed its use in this study.

Primary Outcome

To compare the overall survival in patients with five to fifteen brain metastases who receive SRS compared to patients who receive HA-WBRT + memantine

Conditions Studied

Brain Metastases

Interventions

DRUG Memantine
RADIATION Hippocampal-avoidant (HA-WBRT) Radiotherapy
PROCEDURE Stereotactic Radiosurgery (SRS)

Study Locations (20)

California

City of Hope Corona - Corona
City of Hope Comprehensive Cancer Center - Duarte
City of Hope at Irvine Lennar - Irvine
UC San Diego Moores Cancer Center - La Jolla
City of Hope Antelope Valley - Lancaster
UC Irvine Health/Chao Family Comprehensive Cancer Center - Orange
Kaiser Permanente-Rancho Cordova Cancer Center - Rancho Cordova
Rohnert Park Cancer Center - Rohnert Park
The Permanente Medical Group-Roseville Radiation Oncology - Roseville
South Sacramento Cancer Center - Sacramento
Kaiser Permanente Medical Center - Santa Clara - Santa Clara
City of Hope South Pasadena - South Pasadena
Kaiser Permanente Cancer Treatment Center - South San Francisco
City of Hope South Bay - Torrance
City of Hope Upland - Upland

Florida

Boca Raton Regional Hospital - Boca Raton
UM Sylvester Comprehensive Cancer Center at Coral Gables - Coral Gables
UM Sylvester Comprehensive Cancer Center at Deerfield Beach - Deerfield Beach

Arizona

University of Arizona Cancer Center-Orange Grove Campus - Tucson
University of Arizona Cancer Center-North Campus - Tucson

Trial Details

Field	Value
Enrollment Target	206 participants
Start Date	2018-11-22
Est. Completion	2027-12-31
Phase	Phase 3

Canadian Cancer Trials Group

16 total trials

What NCT03550391 shows while recruiting

NCT03550391 is an interventional study that assigns participants to a tested intervention. The registered 206 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 210-participant average among 67 other Brain Metastases trials with a reported enrollment target.

The record links to 1 condition, with Brain Metastases appearing as the primary indexed condition, and to 3 interventions - of which Memantine is the first listed.

NCT03550391 names 20 study sites across 3 states, led by California, Florida, Arizona.

Frequently Asked Questions

What is clinical trial NCT03550391 about?

NCT03550391 is a clinical study titled "Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases". Stereotactic radiosurgery (SRS) is a commonly used treatment for brain tumors. It is a one-day (or in some cases two day), out-patient procedure during which a high dose of radiation is delivered to small spots in the brain while excluding the surrounding normal brain. Whole brain radiation therapy...

What is the current status of trial NCT03550391?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 206 participants. The study started on 2018-11-22. Estimated completion is 2027-12-31.

What conditions does trial NCT03550391 study?

This clinical trial studies the following conditions: Brain Metastases.

What interventions are being tested in trial NCT03550391?

The interventions under investigation include: Memantine (DRUG), Hippocampal-avoidant (HA-WBRT) Radiotherapy (RADIATION), Stereotactic Radiosurgery (SRS) (PROCEDURE).

Who is sponsoring clinical trial NCT03550391?

This trial is sponsored by Canadian Cancer Trials Group, which has 16 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03550391 being conducted?

This trial has 20 study locations across Arizona, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Brain Metastases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03550391's enrollment target sits among peer trials

206 5th of 67 higher than 63 of 67 other Brain Metastases trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Brain Metastases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

NCT03373968 · 206 participants · Phase 2
Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study
NCT04757116 · 206 participants · NA
Post-Market Study to Assess iTind Safety in Comparison to UroLift
NCT05675865 · 206 participants · NA
Cryoablation for Monomorphic Ventricular Tachycardia
NCT04353778 · 207 participants · Phase 1
Effects of Vagal Dysfunction on Gastrointestinal and Inflammatory Pathways in HIV

Similar registry start date

NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03550391, the US trial registry maintained by the National Library of Medicine. NCT03550391 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.